Ala-Hurula V, Myllyla V, Hokkanen E. Ergotamine abuse: results of ergotamine discontinuation with special reference to the plasma concentrations. Cephalalgia 1982; 2:189-95.
Ala-Hurula V, Myllyla V, Hokkanen E, Tokola O. Tolfenamic acid and ergotamine abuse. Headache 1981; 21:240-2.
Allgulander C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand 1986; 73:465-78.
Baar HA. Treatment for headache: a four-step standardized withdrawal program for analgesic abusers. Pain Clin 1990; 3:173-7 (Abstract).
Bennett WM, DeBroe ME. Analgesic nephropathy: a preventable renal disease. N Engl J Med 1989; 320:1269-71.
Bowdler I, Killian J, Gänsslen-Blumberg S. The association between analgesic abuse and headache-coincidental or causal. Headache 1988; 28:494.
Braithwaite RA. The toxicity of tricyclic and newer antidepressants. In: DeWolff FA, editor. Handbook of clinical neurology. New York: Elsevier Science, 1995:311-20.
Brust JC. Opiate addiction and toxicity, Chapter 16. In: DeWolff FA, editor. Handbook of clinical neurology, Vol. 65. New York: Elsevier Science, 1995:356-61.
Catarci T, Fiacco F, Argentino C. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994; 14:374-5.
Centonze V, Polite BM, diBari M, Caporaletti P, Albano O. Vascular injuries in ergotamine abuse: a case report. Funct Neurol 1993; 8:265-70.
Dalquen P, Fasel J, Mihatsch MJ, Rist M, Rutishauser G. Phenacetinabusus IV. Sind zytologische Harnuntersuchungen in der Tumorvorsorge bei Phenacetinabusern erfolgversprechend und anwendbar. Schweizerische Med Wochenschr 1980; 110:302-6.
DeBroe ME, Elseviers MM. Analgesic nephropathy-still a problem? Nephron 1993; 64:505-13.
deMarinis M, Janiri L, Agnoli A. Headache in the use and withdrawal of opiates and other associated substances of abuse. Headache 1991; 31:159-63.
Diamond S, Dalessio DJ. Drug abuse in headache. In: Diamond S, Dalessio DJ editors. The practicing physician's approach to headache. Baltimore: Williams & Wilkins, 1982:114-21.
Dichgans J, Diener. Clinical manifestations of excessive use of analgesic medication. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:8-15.
Dichgans J, Diener HD, Gerber WD et al. Analgetika-induzierter dauerkopfschmerz. Dtsch Med Wschr 1984; 109:369-73.
Diener HC. A personal view of the classification and definition of drug dependence headache. Cephalalgia 1993; 13:68-71.
Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA editors. The headaches. Philadelphia: Lippincott Williams & Wilkins, 1999:871-8.
Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236:9-14.
Diener HC, Haab J, Peters C, Ried S, Dichgans J, Pilgrim A. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1991; 31:205-9.
Diener HC, Pfaffenrath V, Soyka D, Gerber WD. Therapie des medikamenten-induzierten dauerkopfschmerzes. Münch Med Wschr 1992; 134:159-62.
Diener HC, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA editors. The headaches. New York: Raven Press Ltd, 1993:721-7.
Drucker P, Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998; 38:687-90.
Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality 1968-1979. N Engl J Med 1983; 308:357-62.
Elkind AH. Drug abuse in headache patients. Clin J Pain 1989; 5:111-20.
Elkind AH. Drug abuse and headache. Med Clin N Am 1991; 75:717-32.
Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22:201-6.
Fanciullaci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. Long-term ergotamine abuse: effect on adrenergically induced mydriasis. Clin Pharm Ther 1992; 51:302-7.
Fincham JE. Over-the-counter drug use and misuse by the ambulatory elderly: a review of the literature. J Ger Drug Ther 1987; 1:3-21.
Fincham RW, Perdue Z, Dunn VD. Bilateral focal cortical atrophy and chronic ergotamine abuse. Neurology 1985; 35: 720-2.
Fisher CM. Analgesic rebound headache refuted. Headache 1988; 28:666.
Friedman AP, Brazil P, vonStorch TJ. Ergotamine tolerance in patients with migraine. JAMA 1955; 157:881-4.
Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50:161-5.
Gaist D, Tsiropoulus I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J. Inappropriate use of sumatriptan: population based register and interview study. Br J Med 1998; 316:1352-3.
Granella F, Farina S, Malferrari G, Manzoni GC. Drug abuse in chronic headache: a clinicoepidemiologic study. Cephalalgia 1987; 7:15-9.
Gutzwiller F, Zemp E. Der Analgetikakonsum in der Bevölkerung und socioökonomische Aspekte des Analgetikaabusus. In: Mihatsch MJ editor. Das Analgetikasyndrom. Stuttgart: Thieme, 1986:197-205.
Hering R, Steiner TJ. Abrupt outpatient withdrawal from medication in analgesic-abusing migraineurs. Lancet 1991; 337:1442-3.
Hokkanen E, Waltimo O, Kallanranta T. Toxic effects of ergotamine used for migraine. Headache 1978; 18:95-8.
Horowski R, Ziegler A. Possible pharmacological mechanisms of chronic abuse of analgesics and other anti-migraine drugs. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:95-104.
Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 1963; 3:214-26.
Isler H. Migraine treatment as a cause of chronic migraine. In: Rose FC editor. Advances in migraine research and therapy. New York: Raven Press, 1982:159-64.
Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, Taylor P editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1985:522-73.
Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57:1694-8.
Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. Br Med J 1994; 308:1573.
Kielholz P, Ladewig D. Probleme des medikamentenmi beta-brauches. Schweiz Arztezeitung 1981; 62:2866-9.
Kouyanou K, Pither CE, Rabe-Hesketh S, Wessely S. A comparative study of iatrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Pain 1998; 76:417-26.
Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982; 33:335-41.
Lader M. Hypnotics and sedatives. In: DeWolff FA editor. Handbook of clinical neurology. New York: Elsevier Science, 1995:329-55.
Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headache de novo? Headache 1988; 28:61-2.
Lance JW. A concept of migraine and the search for the ideal headache drug. Headache 1990; 30:17-23.
Limmroth V, Kazarawa S, Pritsche G, Diener HC. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999; 353:378.
Limmroth V, Katsarava Z, Pritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59:1011-4.
Lucas RN, Falkowski W. Ergotamine and methysergide abuse in patients with migraine. Br J Psychiatry 1973; 122:199-203.
Ludolph AC, Husstedt IW, Schlake HP, Grotemeyer KH, Brune GG. Chronic ergotamine abuse: evidence of functional impairment of long ascending spinal tracts. Eur Neurol 1988; 28:311-6.
MacGregor EA, Vorah C, Wilkinson M. Analgesic use: a study of treatments used by patients for migraine prior to attending the City of London migraine clinic. Headache 1990; 30:634-8.
Manzoni GC, Micieli G, Granella F, Sandrini G, Zanferrari C, Nappi G. Therapeutic approach to drug abuse in headache patients. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:143-9.
Marks V. Reactive (rebound) hypoglycemia). In: Marks V, Rose CF editors. Hypoglycemia. Oxford: Blackwell, 1981:179-217.
Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987; 27:130-3.
Mathew NT, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache 1990; 30:634-8.
Michultka DM, Blanchard EB, Appelbaum KA, Jaccard J, Dentinger MP. The refractory headache patient-2. High medication consumption (analgesic rebound) headache. Behav Res Ther 1989; 27:411-20.
Micieli G, Manzoni GC, Granella F, Martignoni E, Malferrari G, Nappi G. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:20-8.
Nicolodi M, DelBianco PL, Sicuteri F. The way to serotonergic use and abuse in migraine. Int J Clin Pharmacol Res 1997; 17:79-84.
Page H. Rebound headache from ergotamine withdrawal. JAMA 1981; 246:719.
Peters G, Horton BT. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Mayo Clin 1951; 26:153-61.
Fini LA, Trenti T. Case report: does chronic use of sumatriptan induce dependence? Headache 1994; 34:600-1.
Pradalier A, Dry S, Baron JF. Cephalée induite par l'abuse de tartrate d'ergotamine chez les migrainieux. Concours Méd 1984; 106:106-10.
Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache 1993; 33:442-5.
Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36:14-9.
Rapoport AM, Weeks RE. Characteristics and treatment of analgesic rebound headache. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:162-7.
Roswell AR, Neylan C, Wilkinson M. Ergotamine induced headache in migrainous patients. Headache 1973; 13:65-7.
Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, Blythe WB, Burgess WP. Analgesic use and chronic renal disease. N Engl J Med 1989; 320:1238-43.
Saper JR. Drug abuse among headache patients. In: Saper JR editor. Headache disorders. Boston: PSG Publishers, 1983:263-78.
Saper JR. Drug overuse among patients with headache. Neurol Clin 1983; 1:465-77.
Saper JR. Daily chronic headaches. Neurol Clin N Am 1990; 8:891-902.
Saper JR, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986; 9:244-56.
Schnider P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year followup. Cephalalgia 1996; 16:481-5.
Schnider P, Aull S, Feucht M. Use and abuse of analgesics in tension-type headache. Cephalalgia 1994; 14:162-7.
Schnider P, Maly J, Grunberger J, Aull S, Zeiler K, Wessely P. Improvement of decreased critical flicker frequency in headache patients with drug abuse after successful withdrawal. Headache 1995; 35:269-72.
Schoenen J, Lenarduzzi P, Sianard-Gainko J. Chronic headaches associated with analgesics and/or ergotamine abuse: a clinical survey of 434 consecutive outpatients. In: Rose FD editor. New advances in headache research. London: Smith-Gordon, 1989: 29-43.
Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994; 34:1-7.
Silberstein SD, Silberstein JR. Chronic daily headache: prognosis following inpatient treatment with repetitive IV DHE. Headache 1992; 32:439-45.
Stewart JH. Analgesic abuse and renal failure in Australia. Kidney Int 1978; 13:72-8.
Sullivan JT, Sellers EM. Treatment of the barbiturate abstinence syndrome. Med J Aust 1986; 145:456-8.
Taschner KL, Wiesbeck GA. Psychiatric aspects of drug addiction of the barbiturate-alcohol type. In: Diener HC, Wilkinson M editors. Drug-induced headache. Berlin: Springer-Verlag, 1988:80-4.
Tfelt-Hansen P. Ergotamine headache. In: Pfaffenrath V, Lundberg P, Sjaastad O editors. Updating in headache. Berlin: Springer, 1985:169-72.
Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 1986; 59:1-29.
Tfelt-Hansen P, Krabbe AA. Ergotamine. Do patients benefit from withdrawal? Cephalalgia 1981; 1:29-32.
Tfelt-Hansen P, Olesen J. Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. Acta Physiol Scand 1981; 48:69-72.
Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985; 37:29-35.
Tfelt-Hansen PPR, Saxena, Ferrari. Ergot alkaloids. In: DeWolff FA editor. Handbook of clinical neurology. New York: Elsevier Science, 1995:61-7.
Timmings PL, Richens. Neurotoxicology of antiepileptic drugs. In: DeWolff FA editor. Handbook of clinical neurology. New York: Elsevier Science, 1995:495-513.
Vasconcellos E, Pina-Garza JE, Millan EJ, Warner JS. Analgesic rebound headache in children and adolescents. J Child Neurol 1998; 13:443-7.
Verhoeff NPLG, Visser WH, Ferrari MD, Saxena PR, van Royen EA. Dopamine D2 receptor imaging with 123-I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier. Cephalalgia 1993; 13:325-9.
VonKorff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain 1995; 62:179-86.
Walker J, Parisi S, Olive D. Analgesic rebound headache: experience in a community hospital. Southern Med J 1993; 86:1202-5.
Warner JS. Rebound headaches: a review. Headache Q 1999; 10:207-19.
Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999; 33:61-72.
Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 2000; 14:5-10.
